Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Harmony Biosciences Holdings (HRMY) Stock Price & Analysis
163 Followers
HRMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.61 - $39.27
Previous Close$30.27
Volume662.11K
Average Volume (3M)416.59K
Market Cap
$1.72B
Enterprise Value$1.56B
Total Cash (Recent Filing)$353.46M
Total Debt (Recent Filing)$193.57M
Price to Earnings (P/E)13.1
Beta0.74
Next Earnings
Jul 30, 2024EPS Estimate
$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.32
Shares Outstanding56,791,861
10 Day Avg. Volume563,551
30 Day Avg. Volume416,594
Standard Deviation0.13
R-Squared0.08
Alpha-0.00156
Financial Highlights & Ratios
Price to Book (P/B)5.32
Price to Sales (P/S)10.21
Price to Cash Flow (P/CF)5.70
P/FCF Ratio5.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda8.74
Forecast
1Y Price Target
$42.67Price Target Upside34.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Harmony Biosciences Holdings News
Bulls Say, Bears Say
Bulls Say
Business DevelopmentAnalyst recommends a higher price target for Harmony Biosciences based on the company's execution of its business development strategy.
Product Lineup ExpansionThe addition of new therapies like EPX-100 is anticipated to strengthen Harmony Biosciences' product lineup.
Strategic AcquisitionsHarmony Biosciences is expanding its CNS portfolio with strategic acquisitions such as Epygenix for epilepsy treatment.
Bears Say
Competition And Market ShareCompetitor's drug could become the second non-scheduled agent approved for narcolepsy, challenging Wakix's unique position.
Drug Development And Approval RisksPlans to file an sNDA for Wakix in idiopathic hypersomnia are challenging after missing statistical significance on primary endpoint.
Legal And Regulatory RisksWakix is subject to ongoing patent litigation with a key litigation milestone approaching, posing a key risk.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $18.61 and its highest was $39.27 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Currently, no data Available
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is Jul 30, 2024 which is in 86 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Apr 30, 2024. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.604 by $0.066.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is $0.24.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 56,791,862 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.67 in its last earnings report, beating expectations of $0.604. Following the earnings report the stock price went up 5.675%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Among the largest hedge funds holding Harmony Biosciences Holdings’s share is Woodline Partners LP. It holds Harmony Biosciences Holdings’s shares valued at 5M.
---
Harmony Biosciences Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.67 (34.65% Upside)
$42.67 (34.65% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.60%
12-Months-Change
Fundamentals
Return on Equity
28.73%
Trailing 12-Months
Asset Growth
18.44%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
---
HRMY Company Deck
---
HRMY Earnings Call
Q1 2024
0:00 / 0:00
---
HRMY Stock 12 Months Forecast
Average Price Target
$42.67
▲(34.65% Upside)
Technical Analysis
Best Analysts Covering HRMY
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-5.97%
reiterated a buy rating 23 days ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -5.97% per trade.
---